Hameed A, Brady J J, Dowling P, et al. Bone disease in multiple myeloma: pathophysiology and management[J]. Cancer Growth Metastasis, 2014, 7: 33-42. [2]Ge X, Wang X. Role of Wnt canonical pathway in hematological malignancies[J]. J Hematol Oncol, 2010, 3: 33. [3]Polakis P. Drugging Wnt signalling in cancer[J]. EMBO J, 2012, 31(12): 2737-2746. [4]De-la-Puente P, Muz B, Azab F, et al. Molecularly targeted therapies in multiple myeloma[J]. Leuk Res Treatment, 2014, 2014: 976567. [5]Redies C, Vanhalst K, Roy Fv. delta-Protocadherins: unique structures and functions[J]. Cell Mol Life Sci, 2005, 62(23): 2840-2852. [6]Li Z, Chim J C, Yang M, et al. Role of PCDH10 and its hypermethylation in human gastric cancer[J]. Biochim Biophys Acta, 2012, 1823(2): 298-305. [7]Narayan G, Xie D, Freddy A J, et al. PCDH10 promoter hypermethylation is frequent in most histologic subtypes of mature lymphoid malignancies and occurs early in lymphomagenesis[J]. Genes Chromosomes Cancer, 2013, 52(11): 1030-1041. [8]Zhong X, Zhu Y, Mao J, et al. Frequent epigenetic silencing of PCDH10 by methylationin human colorectal cancer[J]. J Cancer Res Clin Oncol, 2013, 139(3): 485-490. [9]Wang L, Xie P G, Lin Y L, et al. Aberrant methylation of PCDH10 predicts worse biochemical recurrence-free survival in patients with prostate cancer after radical prostatectomy[J]. Med Sci Monit, 2014, 20: 1363-1368. [10]Yu J, Cheng Y Y, Tao Q, et al. Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer[J]. Gastroenterology, 2009, 136(2): 640-651. e1. [11]Deng J, Liang H, Ying G, et al. Clinical significance of the methylated cytosine-phosphate-guanine sites of protocadherin-10 promoter for evaluating the prognosis of gastric cancer[J]. J Am Coll Surg, 2014, 219(5): 904-913. [12]Li Y, Yang Z S, Song J J, et al. Protocadherin-10 is involved in angiogenesis and methylation correlated with multiple myeloma[J]. Int J Mol Med, 2012, 29(4): 704-710. [13]李颖, 陈建斌, 宋君君, 等. 甲基化修饰致PCDH10基因在多发性骨髓瘤中沉默[J]. 第三军医大学学报, 2012, 34(9): 817-820. [14]李珍, 陈建斌, 彭曦, 等. PCDH10基因促进多发性骨髓瘤细胞凋亡及机制研究[J]. 第三军医大学学报, 2014, 36(5): 437-441. [15]Dallosso A R, Hancock A L, Szemes M, et al. Frequent long-range epigenetic silencing of protocadherin gene clusters on chromosome 5q31 in Wilms’ tumor[J]. PLoS Genet, 2009, 5(11): e1000745. [16]Yang X, Chen M W, Terry S, et al. A human- and male-specific protocadherin that acts through the wnt signaling pathway to induce neuroendocrine transdifferentiation of prostate cancer cells[J]. Cancer Res, 2005, 65(12): 5263-5271. [17]Zhao Y, Yang Y, Trovik J , et al. A novel wnt regulatory axis in endometrioid endometrial cancer[J]. Cancer Res, 2014, 74(18): 5103-5117. [18]彭曦, 陈建斌, 李珍, 等. PCDH10基因在多发性骨髓瘤细胞中的作用[J]. 第三军医大学学报, 2014, 36(20): 2093-2097. [19]Medina M, Garrido J J, Wandosell F G. Modulation of GSK-3 as a Therapeutic Strategy on Tau Pathologies[J]. Front Mol Neurosci, 2011, 4: 24. [20]Kamarudin M N, Mohd-Raflee N A, Hussein S S, et al. (R)-(+)-α-Lipoic acid protected NG108-15 cells against H2O2-induced cell death through PI3K-Akt/GSK-3β pathway and suppression of NF-κβ-cytokines[J]. Drug Des Devel Ther, 2014, 8: 1765-1780. [21]Danese E, Minicozzi A M, Benati M, et al. Epigenetic alteration: new insights moving from tissue to plasma：the example of PCDH10 promoter methylation in colorectal cancer[J]. Br J Cancer, 2013, 109(3): 807-813. [22]Fauriat C, Olive D. AML drug resistance: c-Myc comes into play[J]. Blood, 2014, 123(23): 3528-3530. [23]Xie C, Pan Y, Hao F, et al. C-Myc participates in β-catenin-mediated drug resistance in A549/DDP lung adenocarcinoma cells[J]. APMIS, 2014, 122(12): 1251-1258.
[2]
李宏维,叶凯山,王栓科.外源性BMP9对骨肉瘤细胞MG63的影响与Wnt/β-catenin信号通路的关系[J].第三军医大学学报,2015,37(07):655. Li Hongwei,Ye Kaishan,Wang Shuanke.Effect of exogenous BMP9 on osteosarcoma MG63 cells and its relationship with Wnt/β-catenin signaling pathway[J].J Third Mil Med Univ,2015,37(14):655.
